https://www.bioworld.com/rss en-us Histosonics Inc. signed an exclusive distribution agreement with Gunze Medical Ltd. to bring its novel histotripsy-based therapeutic model, the Edison System, to Japan. The strategic alliance with Gunze Medical, a wholly owned subsidiary of Osaka, Japan-based Gunze Ltd., paves a figurative runway for Histosonics to introduce its Edison platform in Japan — one of Asia’s largest medical device markets. http://www.bioworld.com/articles/724915 Tue, 14 Oct 2025 12:00:00 -0400 https://www.bioworld.com/articles/724915-histosonics-expands-to-japan-with-gunze-pact Histosonics Edison Histosonics Edison histotripsy system. Credit: Histosonics Insightec Ltd. received U.S. FDA approval for use of its Exablate Neuro device to address severe motor symptoms in patients with Parkinson’s disease, offering a new option for patients who have not found adequate relief from medications. Exablate Neuro uses focused ultrasound to create lesions in the brain without requiring an incision or implant. http://www.bioworld.com/articles/721798 Tue, 08 Jul 2025 12:00:00 -0400 https://www.bioworld.com/articles/721798-insightec-gains-fda-approval-for-exablate-neuro-use-in-parkinsons insightec-exablate-neuro-12-13.png Exablate Neuro Helmet. Credit: Insightec Ltd. Less than three years after unveiling the first Sonovein device, Theraclion SA is launching its CE-marked, third-generation platform, Sonovein HD. This represents a new generation of robotics platform for noninvasive treatment of varicose veins. The new version integrates the acquisition and analysis of technical data during the procedure. http://www.bioworld.com/articles/519316 Tue, 31 May 2022 13:00:00 -0400 https://www.bioworld.com/articles/519316-theraclion-launches-new-robotics-vein-platform Varicose veins concept art Toosonix A/S has launched two trials as it moves to gather data enabling its high-intensity focused ultrasound (HIFU) device to get approval for use in clinical dermatology indications. The company reported on April 19 that the first patients have been treated in a trial of its System One-M device in treating basal cell carcinoma (BCC). Meanwhile, the first patient has been cleared for treatment on April 28 in a study in neurofibromatosis, an inherited condition that causes benign tumors to form on the skin. http://www.bioworld.com/articles/518163 Fri, 22 Apr 2022 13:00:00 -0400 https://www.bioworld.com/articles/518163-toosonix-launches-trials-to-evaluate-dermatological-hifu-use